Attenuation of apoptosis in enterocytes by blockade of potassium channels.
Apoptosis plays an important role in maintaining the balance between proliferation and cell loss in the intestinal epithelium. Apoptosis rates may increase in intestinal pathologies such as inflammatory bowel disease and necrotizing enterocolitis, suggesting pharmacological prevention of apoptosis as a therapy for these conditions. Here, we explore the feasibility of this approach using the rat epithelial cell line IEC-6 as a model. On the basis of the known role of K+ efflux in apoptosis in various cell types, we hypothesized that K+ efflux is essential for apoptosis in enterocytes and that pharmacological blockade of this efflux would inhibit apoptosis. By probing intracellular [K+] with the K+-sensitive fluorescent dye and measuring the efflux of 86Rb+, we found that apoptosis-inducing treatment with the proteasome inhibitor MG-132 leads to a twofold increase in K+ efflux from IEC-6 cells. Blockade of K+ efflux with tetraethylammonium, 4-aminopyridine, stromatoxin, chromanol 293B, and the recently described K+ channel inhibitor 48F10 prevents DNA fragmentation, caspase activation, release of cytochrome c from mitochondria, and loss of mitochondrial membrane potential. Thus K+ efflux occurs early in the apoptotic program and is required for the execution of later events. Apoptotic K+ efflux critically depends on activation of p38 MAPK. These results demonstrate for the first time the requirement of K+ channel-mediated K+ efflux for progression of apoptosis in enterocytes and suggest the use of K+ channel blockers to prevent apoptotic cell loss occurring in intestinal pathologies.
Grishin
Anatoly
A
Division of Pediatric Surgery, Children's Hospital of Los Angeles, Los Angeles, California, USA.
Ford
Henri
H
Wang
Jin
J
Li
Hui
H
Salvador-Recatala
Vicenta
V
Levitan
Edwin S
ES
Zaks-Makhina
Elena
E
D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D001643:Bridged Bicyclo Compounds / Q000494:pharmacology*; D002460:Cell Line; D019610:Cytoprotection / Q000187:drug effects; D020895:Enterocytes / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D011188:Potassium / Q000378:metabolism; D026902:Potassium Channel Blockers / Q000494:pharmacology*; D024642:Potassium Channels, Voltage-Gated / Q000037:antagonists & inhibitors* / Q000378:metabolism; D051381:Rats; D048051:p38 Mitogen-Activated Protein Kinases / Q000378:metabolism
C481601:3-bicyclo(2.2.1)hept-2-yl-benzene-1,2-diol; D001643:Bridged Bicyclo Compounds; D026902:Potassium Channel Blockers; D024642:Potassium Channels, Voltage-Gated; D048051:p38 Mitogen-Activated Protein Kinases; D011188:Potassium